Triptorelin
After an initial surge, continuous use shuts down sex-hormone production; used for prostate cancer, endometriosis and early puberty.
Prescription-only (e.g. Trelstar).
Look it up on Wikipedia3 listings across 2 independently tested vendors, ranked by price per milligram after coupon codes anyone can use. Vendors you can only order from by message are hidden.
FDA-approved (Trelstar, Triptodur).
Daily price tracking started October 7, 2026; a price-history chart appears here once a few days have been collected.
| Vendor | Trust | Listing | Vials | Price | Per mg | |
|---|---|---|---|---|---|---|
Qingdao Sigma Chemical QSC #69 by metascore |
Triptorelin 2mg | 20-Vial Kit | GnRH Agonist | 20 × 2 mg = 40 mg | $330.00 $16.50 per vial |
$8.25 | Buy | |
Qingdao Sigma Chemical QSC #69 by metascore |
Triptorelin 2mg | 10-Vial Kit | GnRH Agonist | 10 × 2 mg = 20 mg | $190.00 $19.00 per vial |
$9.50 | Buy | |
Core Peptides #282 by metascore |
Metascore 70 medium confidenceFinnrick 76%PepIndex 24/100Bought vials 92% of label · 4 testsTitrateLab · PeptideBase · Peptide Critic · PeptideCheckedNo report for thisOnline checkout |
Triptorelin – 2MG | 1 × 2 mg | $54.00 | $27.00 | Buy |
Mixing a 2 mg vial
What each common amount of bacteriostatic water gives you on a U-100 insulin syringe. Pick a vial size above to change it.
| Water | Strength | Per 10 units (0.1 mL) | Per unit |
|---|---|---|---|
| 1 mL | 2 mg/mL | 200 mcg | 20 mcg |
| 2 mL | 1 mg/mL | 100 mcg | 10 mcg |
| 3 mL | 0.667 mg/mL | 66.7 mcg | 6.67 mcg |
| 5 mL | 0.4 mg/mL | 40 mcg | 4 mcg |
Doses studied in research Approved drug
What was given to people (or animals) in published studies and official labels, each linked to its source. This is not a recommendation: study products, purity and supervision differ from research-grade vials.
single intramuscular injection in either buttock: 3.75 mg every 4 weeks, 11.25 mg every 12 weeks, or 22.5 mg every 24 weeks (strengths are not additive) (intramuscular)
Official label22.5 mg as a single intramuscular injection once every 24 weeks, given by a healthcare provider (intramuscular)
Official label| Who was studied | Dose given | How often | For how long | What happened | |
|---|---|---|---|---|---|
| women aged 18-45 with endometriosis (phase 3 RCT) n = 300 |
15 mg (3-month pamoate) or 3.75 mg (1-month acetate) per injection intramuscular injection (prolonged-release) | every 12 weeks or every 4 weeks | 6 months | over 98% in both groups had estradiol suppressed to castration levels at week 12; similar pelvic-pain reduction | PubMed |
| children with central precocious puberty (phase 3, single arm) n = 66 |
22.5 mg triptorelin pamoate injection (6-month prolonged-release) | two doses, day 1 and month 6 | 12 months | LH suppressed in all children at month 6 and 98.5% at month 12; growth velocity fell from 9.82 to 5.17 cm/year | PubMed |
| children with central precocious puberty (meta-analysis) n = 153 |
11.25 mg intramuscular | every 3 months | 3 to 6 months | peak LH suppressed in 87.6% at 3 months and 92.8% at 6 months | PubMed |
| men with localized prostate cancer before radical prostatectomy (RCT) n = 111 |
3.75 mg (with cyproterone acetate 50 mg twice daily for 3 weeks against flare) intramuscular | every 28 days | 3 months before surgery | positive surgical margins 23% vs 41% with immediate surgery; no difference in blood loss or operating time | PubMed |
| girls with puberty onset at 7.5-8.5 years (RCT vs no treatment) n = 46 |
3.75 mg intramuscular | every 4 weeks | until treatment stop (not stated in abstract) | menarche delayed (11.9 vs 10.8 years) but final height not different (158.1 vs 158.6 cm) | PubMed |
| teenage boys with delayed puberty or gonadotropin deficiency (diagnostic test) | 0.1 mg/m2 subcutaneous | single injection | single dose, hormones measured after 4 hours | gonadotropin and testosterone rise was greater in delayed puberty than in gonadotropin deficiency | PubMed |
Approved triptorelin regimens are long-acting depots designed to suppress sex hormones. No study in our candidate pool tested a single dose to restore testosterone after anabolic steroid use.
What the research says
Triptorelin is an approved long-acting GnRH agonist with extensive human RCT and meta-analysis evidence for suppressing sex hormones in prostate cancer, breast cancer, endometriosis and precocious puberty. Its sustained effect is to shut down, not stimulate, the reproductive axis; no study in the candidates tests the off-label single-dose use to 'restart' testosterone after anabolic steroids.
Key papers ✓ 5✗ 1~ 1? 1
-
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.Humans4,690 peopleRandomized5 years of therapy; median follow-up 68 monthsTwo phase 3 randomized trials, combined analysis; ovarian suppression by triptorelin, oophorectomy or ovarian irradiation
SOFT/TEXT trials in 4,690 premenopausal women with hormone-receptor-positive breast cancer (ovarian suppression mostly with triptorelin): exemestane plus suppression improved 5-year disease-free survival vs tamoxifen plus suppression (91.1% vs 87.3%); grade 3-4 adverse events ~30% in both arms.
Key result5-year disease-free survival 91.1% vs 87.3% (HR 0.72; 95% CI 0.60 to 0.85; P<0.001); overall survival not different (HR 1.14; P=0.37)
Study details
- Studied
- Premenopausal women with hormone-receptor-positive early breast cancer
- Compared with
- Tamoxifen plus ovarian suppression
- Main outcome
- Disease-free survival at 5 years
- Sample
- 4690 premenopausal women pooled from the SOFT and TEXT trials
- Authors' conclusion
- In premenopausal women, exemestane plus ovarian suppression significantly reduced recurrence compared with tamoxifen plus ovarian suppression.
- Limitations
- Ovarian suppression was triptorelin in some patients only; the comparison is of the aromatase inhibitor, not of triptorelin itself.
-
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.Humans7,030 peopleRandomized trialsMedian follow-up 8.0 yearsPatient-level meta-analysis of four randomised trials
Patient-level meta-analysis of 7,030 premenopausal women receiving ovarian suppression (goserelin or triptorelin): an aromatase inhibitor reduced breast cancer recurrence vs tamoxifen (RR 0.79), without a difference in mortality; more fractures with aromatase inhibitors.
Key resultRecurrence lower with aromatase inhibitor (RR 0.79, 95% CI 0.69-0.90, p=0.0005); breast cancer mortality RR 1.01 (95% CI 0.82-1.24; p=0.94); fractures 6.4% vs 5.1% (p=0.017)
Study details
- Studied
- Premenopausal women with ER-positive early breast cancer receiving ovarian suppression (goserelin or triptorelin) or ablation
- Compared with
- Tamoxifen
- Main outcome
- Breast cancer recurrence, breast cancer mortality, all-cause mortality
- Sample
- 7030 women from four randomised trials
- Authors' conclusion
- Using an aromatase inhibitor rather than tamoxifen in premenopausal women receiving ovarian suppression reduces recurrence risk; longer follow-up is needed for any effect on mortality.
- Limitations
- Compares aromatase inhibitor vs tamoxifen, not triptorelin; ovarian suppression agent included goserelin.
-
Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation .Humans153 people3 and 6 monthsMeta-analysis of clinical studies of triptorelin 11.25 mg 3-month formulation
Meta-analysis of 153 children with central precocious puberty: the 3-month triptorelin formulation suppressed the LH response in 87.6% at 3 months and 92.8% at 6 months.
Key resultSuppressed peak LH in 87.6% (95% CI 81.3-92.4) at 3 months and 92.8% (95% CI 87.5-96.4) at 6 months
Study details
- Studied
- Children with central precocious puberty
- Main outcome
- Proportion with suppressed peak LH response to GnRH test
- Sample
- 153 children (13 boys, 140 girls) in a meta-analysis of all available studies
- Authors' conclusion
- The triptorelin 11.25 mg 3-month formulation is efficacious in suppressing LH peak and other gonadal hormones and slowing the progression of CPP in children.
- Limitations
- Mostly girls; single-arm pooled data without a control group.
-
Assessment of Two Formulations of Triptorelin in Chinese Patients with Endometriosis: A Phase 3, Randomized Controlled Trial.Humans300 peopleRandomizedOpen-label6 months of treatment; primary outcome at 12 weeksPhase 3 randomized, open-label, active-controlled, multicenter noninferiority trial
300 women with endometriosis: 3-month triptorelin was noninferior to the 1-month formulation, with over 98% reaching castration-level estradiol at 12 weeks and similar pelvic-pain reduction.
Key resultOver 98% of patients in both groups were chemically castrated at week 12
Study details
- Studied
- Chinese women aged 18-45 with endometriosis needing GnRH agonist treatment for 6 months
- Compared with
- Triptorelin acetate PR 1-month (3.75 mg every 4 weeks)
- Main outcome
- Proportion with estradiol suppressed to castration level at 12 weeks
- Sample
- 300 Chinese women, 150 per arm
- Authors' conclusion
- Triptorelin pamoate PR 3-month was noninferior to the 1-month formulation, equally efficacious for pelvic pain, with no new safety concerns and fewer injections.
- Limitations
- Open-label design.
-
Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years.Humanssize not reportedRandomizedFollowed to final heightRandomised trial: triptorelin vs no treatment
46 girls with puberty onset at 7.5-8.5 years randomized to triptorelin or no treatment: final adult height was the same (158.1 vs 158.6 cm).
Key resultFinal height 158.1 (6.2) cm with triptorelin vs 158.6 (6.0) cm without treatment, not significantly different
Study details
- Studied
- Girls with onset of puberty aged 7.5-8.5 years
- Compared with
- No treatment
- Main outcome
- Final adult height
- Sample
- Forty-six girls (written as words), 20 in treatment group and 18 analysed in controls
- Authors' conclusion
- LHRH analogue has no apparent effect on final height in girls with onset of puberty between 7.5 and 8.5 years.
- Limitations
- Small trial with no placebo (untreated control).
-
Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study.Humanssize not reportedRandomized48 weeksRandomized clinical study: subcapsular orchiectomy vs triptorelin 22.5 mg depot every 24 weeks
58 men with advanced prostate cancer randomized to triptorelin depot or orchiectomy: androgen deprivation by either route increased fat mass, cholesterol and insulin resistance and reduced lean mass within 12-24 weeks; orchiectomy caused more fat gain.
Key resultNo difference in fasting glucose change (0.2 mmol/L, 95% CI -0.1, 0.4; P = 0.32); orchiectomy had greater total fat mass gain (+2.06 kg, 95% CI 0.55, 3.56) at 48 weeks
Study details
- Studied
- Hormone-naive men with advanced prostate cancer
- Compared with
- Orchiectomy
- Main outcome
- Change in fasting plasma glucose; body composition, lipids, insulin resistance
- Sample
- Fifty-eight men randomised 1:1 (written as words)
- Authors' conclusion
- Androgen deprivation therapy worsens body composition, insulin resistance and cholesterol within 12-24 weeks; orchiectomy causes greater fat accumulation than GnRH agonists.
- Limitations
- Comparison is triptorelin vs orchiectomy; no untreated control group.
-
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients.Humans281 peopleRandomizedOpen-labelMedian follow-up 12.4 yearsMulticenter randomized open-label phase III superiority trial (PROMISE-GIM6), long-term post hoc analysis
PROMISE-GIM6 trial in 281 premenopausal breast cancer patients: adding triptorelin during chemotherapy (to protect ovarian function) did not worsen 12-year disease-free or overall survival.
Key result12-year DFS 65.7% vs 69.2% (HR = 1.16, 95% CI = 0.76 to 1.77); 12-year OS 81.2% vs 81.3% (HR = 1.17, 95% CI = 0.67 to 2.03)
Study details
- Studied
- Premenopausal women with early breast cancer (80.4% hormone receptor-positive) receiving (neo)adjuvant chemotherapy
- Compared with
- Chemotherapy alone
- Main outcome
- 12-year disease-free and overall survival (post hoc)
- Sample
- 281 randomly assigned patients
- Authors' conclusion
- Final analysis provides reassuring results on the safety of GnRHa during chemotherapy for ovarian function preservation, including in hormone receptor-positive disease.
- Limitations
- Survival endpoints were post hoc; open-label.
-
Use of the gonadotropin-releasing hormone agonist triptorelin in the diagnosis of delayed puberty in boys.Humanssize not reportedBlood sampled at baseline and 4 hours after injectionDiagnostic test: single subcutaneous triptorelin 0.1 mg/m2 at 4 AM
In teenage boys, a single triptorelin injection raised gonadotropins and testosterone more in constitutional delayed puberty than in gonadotropin deficiency, supporting its use as a diagnostic test.
Study details
- Studied
- Teenage boys with delayed puberty or gonadotropin deficiency
- Compared with
- Boys with gonadotropin deficiency vs delayed puberty
- Main outcome
- Rise in serum gonadotropins and testosterone
- Sample
- Number of boys not stated in the abstract
- Authors' conclusion
- The increase in blood gonadotropin and testosterone levels was significantly greater in boys with delayed puberty than in those with gonadotropin deficiency.
- Limitations
- Abstract gives no sample size or numerical data.
Reported side effects
- commonHot flashes (with complete androgen ablation incl. triptorelin + flutamide) [ref]
- commonIncreased fat mass, insulin resistance and cholesterol; reduced lean mass [ref]
- commonDrug-related adverse events in children (none grade 3+) [ref]
- reportedSlowed growth, increased BMI and bone-health risks (adolescent puberty suppression) [ref]
Adverse effects largely reflect intended sex-hormone suppression; there is no published human safety data in the candidates on single-dose use in men after anabolic steroid cycles.
167 registered human trials (28 active)
✓ positive · ✗ negative · ~ mixed · ? inconclusive, judged on each paper's own main outcome. Grades: A strong human evidence → D little or none. Papers and verdicts are drawn from PubMed, Europe PMC and Russian journals (CyberLeninka); not medical advice.
Registered clinical trials 167 on ClinicalTrials.gov · 28 active · 77 completed · 33 with posted results
All 167 Triptorelin trials, with countries and summaries · Search ClinicalTrials.gov · Recruiting trials for every peptide
Discussions elsewhere
Experiences and questions about Triptorelin on other sites. Treat anecdotes with care.
Triptorelin: questions people ask
What is Triptorelin?
GnRH agonist. After an initial surge, continuous use shuts down sex-hormone production; used for prostate cancer, endometriosis and early puberty.
How much does Triptorelin cost?
The cheapest Triptorelin from an independently tested vendor is $8.25 per mg (Qingdao Sigma Chemical QSC, Triptorelin 2mg | 20-Vial Kit | GnRH Agonist, $330.00). Across 3 listings from 2 vendors the median is $9.50 per mg.
Where can I buy Triptorelin?
2 vendors tested by Finnrick sell Triptorelin. The cheapest per mg right now: Qingdao Sigma Chemical QSC ($8.25), Core Peptides ($27.00). 0 of them publish a lab report (COA) for Triptorelin; compare lab scores and reports in the table above before buying.
How much bacteriostatic water for 2 mg of Triptorelin?
Adding 2 mL of bacteriostatic water to a 2 mg vial of Triptorelin gives 1 mg/mL: each 10 units on a U-100 insulin syringe holds 100 mcg. With 1 mL it's 2 mg/mL (200 mcg per 10 units); with 3 mL, 0.667 mg/mL (66.7 mcg per 10 units). More water makes small amounts easier to measure. Mixing charts: 2 mg.
Is Triptorelin FDA approved?
Prescription-only (e.g. Trelstar).
Can Triptorelin be compounded in the US?
FDA-approved (Trelstar, Triptodur). Compounding status for every peptide.
Does Triptorelin work? What does the research say?
Evidence grade A (strong human evidence), from 8 papers: Approved drug; large RCTs and meta-analyses (thousands of patients) consistently show hormone suppression for cancers, endometriosis and early puberty. Triptorelin is an approved long-acting GnRH agonist with extensive human RCT and meta-analysis evidence for suppressing sex hormones in prostate cancer, breast cancer, endometriosis and precocious puberty. Its sustained effect is to shut down, not stimulate, the reproductive axis; no study in the candidates tests the off-label single-dose use to 'restart' testosterone after anabolic steroids. See the papers.
Are there clinical trials of Triptorelin?
ClinicalTrials.gov lists 167 registered trials of Triptorelin: 28 active, 77 completed, 59 in phase 3, 33 with posted results. Examples: Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients (Recruiting, 3,000 people); Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (Active, not recruiting, Phase 3, 2,753 people); Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (Active, not recruiting, Phase 3, 2,050 people).
What dose of Triptorelin was used in studies?
Triptorelin is an approved drug. Trelstar (triptorelin pamoate): single intramuscular injection in either buttock: 3.75 mg every 4 weeks, 11.25 mg every 12 weeks, or 22.5 mg every 24 weeks (strengths are not additive); Triptodur (triptorelin): 22.5 mg as a single intramuscular injection once every 24 weeks, given by a healthcare provider; women aged 18-45 with endometriosis (phase 3 RCT): 15 mg (3-month pamoate) or 3.75 mg (1-month acetate) per injection every 12 weeks or every 4 weeks. These are amounts used in published studies or official labels, not a recommendation.
What are the side effects of Triptorelin?
Reported in the research: Hot flashes (with complete androgen ablation incl. triptorelin + flutamide); Increased fat mass, insulin resistance and cholesterol; reduced lean mass; Drug-related adverse events in children (none grade 3+); Slowed growth, increased BMI and bone-health risks (adolescent puberty suppression). Adverse effects largely reflect intended sex-hormone suppression; there is no published human safety data in the candidates on single-dose use in men after anabolic steroid cycles.